- Home
- IOBT vs BRNS Comparison
IOBT vs BRNS Comparison
Compare IOBT & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOBT | BRNS |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Denmark | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 55.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IOBT | BRNS |
|---|---|---|
| Price | $0.32 | $0.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.25 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 27.2M | 47.4K |
| Earning Date | 11-14-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $0.21 | $0.64 |
| 52 Week High | $2.79 | $2.92 |
Technical Indicators
Market Signals| Indicator | IOBT | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 44.18 |
| Support Level | $0.30 | $0.71 |
| Resistance Level | $0.58 | $0.75 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 27.08 | 5.60 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.